Description
Taylor & Francis Cholesterol-Lowering Therapy Evaluation of Clinical Trial Evidence 2000 Edition by Scott M. Grundy
Reveals important new results from clinical trials conducted in Scandinavia, Scotland, Australia, Canada, and the United States.This timely reference reviews the vast body of clinical trial evidence supporting the once controversial view that high levels of serum cholesterol are a major risk factor in coronary heart disease (CHD). The studies presented in Cholesterol-Lowering Therapy: Evaluation of Clinical Trial Evidence promote cholesterol reduction as a highly successful means of preventing heart disease in various populations.Investigates past, current, and upcoming controlled clinical trials of cholesterol-reduction therapies, comparing effects of statins and bile acid sequestrants to triglyceride-lowering drugs and antioxidants.Written by more than 25 distinguished international researchers, Cholesterol-Lowering Therapy: Evaluation of Clinical Trial Evidence highlights historical studies of dietary trials designed to reduce CHD covers tests of HMG CoA reductase inhibitors for patients with and without CHD illuminates CHD risk factors such as diabetes, hypertension, obesity, and smoking explores blood levels of homocysteine and lipoprotein(a) and other recently identified CHD risk factors reviews metabolism of lipoproteins expressed in high (HDL) and low (LDL) density lipoprotein cholesterol and more!Containing over 700 instructive tables, drawings, photographs, and bibliographic citations, Cholesterol-Lowering Therapy: Evaluation of Clinical Trial Evidence is a must-read resource for cardiologists, pharmacologists, and upper-level undergraduate, graduate, and medical school students in these disciplines. Table of contents : - Cholesterol-Lowering Clinical Trials: A Historical PerspectiveScott M. GrundyScandinavian Simvastatin Survival Study (4S)Terje R. PedersenThe Cholesterol and Recurrent Events Trial (CARE): The Effect of Pravastatin on Coronary Events After Myocardial Infarction in Patients with Average Cholesterol LevelsFrank M. Sacks, Marc A. Pfeffer, Lemuel A. Moye, C. Morton Hawkins, Barry R. Davis, Jean L. Rouleau, Thomas G. Cole, and Eugene BraunwaldLessons from the West of Scotland Coronary Prevention Study (WOSCOPS)James Shepherd and Allan GawProgram on the Surgical Control of the Hyperlipidemias (POSCH) Trial: A Pivotal 25-Year StudyHenry BuchwaldThe Air Force/Texas Atherosclerosis Prevention Study (AFCAPS/TexCAPS): Primary Prevention of Acute Major Coronary Events in Women and Men with Average CholesterolStephen Weis, Michael Clearfield, Lt. Col. John R. Downs, and Antonio M. Gotto, Jr.Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study: Clinical Implications for Cardiovascular PracticeAndrew M. Tonkin and David HuntAngiographic Results of Lipid-Lowering Trials: A Systematic Review and Meta-AnalysisCheryl L. Holmes, Michael Schulzer, and G. B. John ManciniBiochemical Correlates of Plaque Progression and Coronary EventsMelissa Ferraro-Borgida and David WatersLipid Therapy to Stabilize the Vulnerable Atherosclerotic Plaque: New Insights into the Prevention of Cardiovascular EventsB. Greg Brown and Xue-Qiao ZhaoCholesterol-Lowering Trials with Carotid Ultrasonographic OutcomesRobert P. ByingtonCholesterol Lowering Reduces Mortality: The StatinsDavid J. Gordon